Vaccine technology: Looking to the future

Annals of Medicine

Volumn 31, Issue 1, 1999, Pages 51-60

  Dorner, Friedrich ^a   Barrett, P Noel ^a  

^a BAXTER INNOVATIONS GMBH   (Austria)

Author keywords

Attenuated micro organisms; Combination vaccines; Immune response; Inactivated vaccine; Recombinant DNA; Vectors

Indexed keywords

LIVE VACCINE; VACCINE;

ARTICLE; MORBIDITY; MORTALITY; POPULATION GROWTH; PRIORITY JOURNAL; VACCINATION;

EID: 0033014167     PISSN: 07853890     EISSN: None     Source Type: Journal    
DOI: 10.3109/07853899909019262     Document Type: Article

References (47)

1. Tiollais P, Pourcel C, Dejean A. The hepatitis B virus. Nature 1985; 317: 489-95.
2. Hilleman MR. Vaccine perspectives from the vantage of hepatitis B. Vaccine Res 1992; 1: 1-15.
3. Pizza M, Covacci A, Bartoloni A, Perugini M, Nencioni L, De Magistris MT, et al. Mutants of pertussis toxin suitable for vaccine development. Science 1989; 246: 497-9.
4. Almond JW. The attenuation of poliovirus neurovirulence. Annu Rev Microbiol 1987; 41: 153-80.
5. Sutter G, Wyatt LS, Foley PL, Bennink JR, Moss B. A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus. Vaccine 1994; 12: 1032-40.
6. Bishop RF, Barnes GL, Cipiranti E, Lund JS. Clinical immunity after neonatal rotavirus infection: a prospective longitudinal study in young children. N Engl J Med 1983; 309: 72.
7. Maassab HF, DeBorde DC. Development and characterization of cold-adapted viruses for use as live virus vaccines. Vaccine 1985; 3: 355-71.
8. Bloom BR, Fine PEM. The BCG experience: implications for future vaccines against tuberculosis. In: Bloom BR, ed. Tuberculosis: Pathogenesis, Protection, and Control. Washington, DC: ASM Press; 1994: 531-58.
9. Levine MM. Typhoid fever vaccines. In: Plotkin SA, Mortimer EA, eds. Vaccines. 2nd edn. Philadelphia, PA: Saunders; 1994: 597-634.
10. Tartaglia J, Perkus ME, Taylor J. NYVAC: a highly attenuated strain of vaccinia virus. Virology 1992; 188: 217-32.
11. Daniel MD, Kirchhoff F, Czajak SC, Sehgal PK, Desrosiers RC. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 1992; 258: 1938-40.
12. Chanock RM, Murphy BR, Collins PL, Coelingh KV, Olmsted RA, Snyder MH, et al. Live viral vaccines for respiratory and enteric tract diseases. Vaccine 1988; 6: 129-33.
13. Kilbourne ED. Inactivated influenza vaccines. In: Plotkin SA, Mortimer EA, eds. Vaccines. 2nd edn. Philadelphia, PA: Saunders; 1994: 565-81.
14. Mortimer EA. Pertussis vaccine. In: Plotkin SA, Mortimer EA, eds. Vaccines. 2nd edn. Phildelphia, PA: Saunders; 1994: 91-136.
15. Jones FG, Moss JM. Studies on tetanus toxoid. I. The antitoxic titer of human subject following immunization with tetanus toxoid and tetanus alum precipitated toxoid. J Immnnol 1936; 30: 115-25.
16. Milch DR. Immune response to hepatitis B virus: infection, animal models, vaccination. Viral Hepatis, Vol 3. Vienna, Austria: Springer Verlag; 1997; 63-103.
17. Meignier B, Longnecker R, Roizman B. In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: construction and evaluation in rodents. J Infect Dis 1988; 158: 602-14.
18. Iizuka N, Kohara M, Hagino-Yamagishi K, Abe S, Komatsu T, Tago K, et al. Construction of less neurovirulent polioviruses by introducing deletions into the 5'-noncoding sequence of the genome. J Virol 1989; 63: 5354-63.
19. Kaper JB, Tacket CO, Levine MM. New and improved vaccines against cholera. In: Levine MM, Woodrow GC, Kaper JB, Cobon GS, eds. New Generation Vaccines. 2nd edn. New York: Marcel Dekker; 1997: 447-58.
20. Levine MM, Tacket CO, Galen JE, Barry EM, Chatfield SN, Dougan G, et al. Progress in development of new attenuated strains of Salmonella typhi as live oral vaccines. In: Levine MM, Woodrow GC, Kaper JB, Cobon GS, eds. New Generation Vaccines. 2nd edn. New York: Marcel Dekker; 1997: 437-46.
21. Valenzuela P, Medina A, Rutter WJ, Ammener G, Hall BD. Synthesis and assembly of hepatitis B virus surface antigen particles in yeast. Nature 1982; 298: 347-50.
22. Adamowicz P, Tron F, Vinas R, Mevelec MN, Diaz I, Couroucé AM, et al. Hepatitis B vaccine containing the S and preS-2 antigens produced in Chinese hamster ovary cells. In: Zuckerman AJ, ed. Viral Hepatitis and Liver Disease. New York: Alan R Liss; 1988: 263-90.
23. Paoletti E, Lipinskas BR, Samsonoff C, Mercer S, Panicali D. Construction of live vaccines using genetically engineered poxviruses: biological activity of vaccinia virus recombinants expressing the hepatitis B virus surface antigen and the herpes simplex virus glycoprotein D. Proc Natl Acad Sci U S A 1984; 81: 193-7.
24. Jacobs WR Jr, Snapper SB, Lugosi L, Bloom BR. Development of BCG as a recombinant vaccine vehicle. Curr Top Microbiol Immunol 1990; 155: 153-60.
25. Donnelly JJ, Ulmer JB, Liu MA. Immunization with DNA. J Immunol Methods 1994; 176: 145-52.
26. Chai SK, Clavijo P, Tam JP, Zavala F. Immunogenic properties of multiple antigen peptide systems containing defined T-epitope and B-epitope. J Immunol 1992; 147: 2385-90.
27. Grzych JM, Capron M, Lambert PH, Dissous C, Torres S, Capron A. An anti-idiotype vaccine against experimental schistosomiasis. Nature 1985; 316: 74-6.
28. Siber GR. Pneumococcal disease: prospects for a new generation of vaccines. Science 1994; 265: 1385-7.
29. Arntzen CJ, Mason HS, Shi J, Haq TA, Estes MK, Clements JD. Transgenic plants as vaccine production systems. In: Brown F, Chanock RM, Ginsberg HS, Lerner RA, eds. Vaccines '94: Modern Approaches to New Vaccines Including Prevention of AIDS. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press: 1994; 239-244.
30. Mason HS, Lam DMK, Arntzen CJ. Expression of hepatitis B surface antigen in transgenic plants. Proc Natl Acad Sci U S A 1992; 89: 11745-9.
31. May GD, Afza R, Mason HS, Weicko A, Novak FJ, Arntzen CJ. Generation of transgenic banana (Musa acuminata) plants via Agrobacterium-mediated transformation. Biotechnology (NY) 1995; 13: 486-92.
32. McGarvey PB, Hammond J, Dienelt MM, Hooper DC, Fu ZF, Dietzschold B, et al. Expression of the rabies virus glycoprotein in transgenic tomatoes. Biotechnology 1995; 13: 1484-7.
33. Mason HS, Arntzen CJ. Transgenic plants as vaccine production systems. Trends Biotechnol 1995; 13: 388-92.
34. Gupta RK, Siber GR. Adjuvants for human vaccines -current status, problems and future prospects. Vaccine 1995; 14: 1263-76.
35. Morris W, Steinhoff MC, Russell PK. Potential of polymer microencapsulation technology for vaccine innovation. Vaccine 1994; 12: 5-11.
36. Heath AW, Playfair JHL. Cytokines as immunological adjuvants. Vaccine 1992; 10: 427-34.
37. Valensi JPM, Carlson JR, Van Nest GA. Systemic cytokine profiles in BALB/c mice immunized with trivalent influenza vaccine containing MF59 oil emulsion and other advanced adjuvants. J Immunol 1994; 143: 4029-39.
38. Stürchler D, Berger R, Etlinger H, Fernex M, Matile H, Pink R, et al. Effects of interferons on immune response to a synthetic peptide malaria sporozoite vaccine in non-immune adults. Vaccine 1989; 7: 457-61.
39. André FE, Peetermans J. Effect of simultaneous administration of live measles vaccine on the "take rate" of live mumps vaccine. Dev Biol Stand 1986; 65: 101-7.
40. Arbeter AM, Baker L, Starr SE, Levine BL, Books E, Plotkin SA. Combination measles, mumps, rubella and varicella vaccine. Pediatrics 1986; 78(4 Pt 2): 742-7.
41. Dagan R, Botujansky C, Watemberg N, Arbelli Y, Belmaker I, Ethevenaux C, et al. Safety and immunogenicity in young infants of Haemophilus b-tetanus protein conjugate vaccine, mixed in the same syringe with diphtheria-tetanus-pertussis-enhanced inactivated poliovirus vaccine. Pediatr Infect Dis J 1994; 13: 356-61.
42. André FE. Development of combined vaccines: manufacturers' viewpoint. Biologicals 1994; 22: 317-21.
43. Rogers BL, Morgenstern JP, Griffith IJ, Yu XB, Counsell CM, Brauer AW, et al. Complete sequence of the allergen Amb alpha II. Recombinant expression and reactivity with T cells from ragweed allergic patients. J Immunol 1991; 147: 2547-52.
44. Ada GL, Griffin PD, eds. Vaccines for Fertility Regulation: The Assessment of Their Safety and Efficacy. Cambridge, UK: Cambridge University Press; 1991.
45. Hellström I, Hellström KE. Tumor immunology: an overview. Ann N Y Acad Sci 1993; 690: 24-33.
46. Fenner F, Henderson DA, Arita I, Jazek Z, Ladnyi IO. Smallpox and Its Eradication. Geneva: World Health Organization; 1988.
47. The Americas conquer polio! EPI Newsletter 1994; 4: 1-3.